Amyris, Inc. (NASDAQ:AMRS) Sees Stock Price Rise – Up by 5.83%


(NASDAQ:AMRS) is trading up by 5.83% percent from yesterday’s close and is one of the top gainers in today’s market. 105,470 shares have changed hands.

Company shares are trading at $3.63 significantly above $2.84, the 50 day moving average and a great deal lower than the 200 day moving average of $4.78. The 50 day moving average was up by +28.02% and the 200 day average moved down $-1.15.

Traders are a little more bearish on shares of the company of late as indicated by the increase in short interest. The company realized a rise in short interest from August 15, 2017 to August 31, 2017 of 20.37%. Short interest increased from 2,517,021 to 3,029,684 over that period. With short interest at 3,029,684 and short average daily volume at 345,737, the short-interest ratio is 9.0 and the short interest percentage is 0.13% as of August 31.

Here are a few substantial investment firms who have updated their positions. As of quarter end Tpg Group Holdings (sbs) Advisors, Inc. had sold 3,713,416 shares trimming its holdings by 93.3%. The value of the company’s investment in Amyris, Inc. decreased from $2,109,000 to $843,000 a change of 60.0% for the reporting period. As of the end of the quarter Nelson Roberts Investment Advisors, LLC had disposed of a total of 2,065 shares trimming its stake by 93.3%. The value of the total investment in Amyris, Inc. went from $1,000 to $0 decreasing 100.0% quarter to quarter.

Morgan Stanley reduced its ownership by selling 44,731 shares a decrease of 98.2%. Morgan Stanley now controls 828 shares with a value of $0. The value of the position overall is down by 100.0%. As of quarter end Goldman Sachs Group Inc had bought a total of 44,981 shares growing its position 270.9%. The value of the investment in AMRS went from $12,000 to $33,000 a change of $21,000 since the last quarter.

As of the latest earnings report the EPS was $-6.02 and is expected to be $-3.32 for the current year with 37,606,000 shares currently outstanding. Next quarter’s EPS is forecasted to be $-0.16 and the next full year EPS is anticipated to be $-1.84.

Amyris, Inc., launched on April 15, 2010, is an integrated industrial biotechnology company. The Company is involved in research and development and sales of fuels and farnesene-derived products. The Company is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels. The Company intends to apply its technology to the development of pharmaceutical products. The Company focuses on a renewable hydrocarbon molecule called farnesene (Biofene), which forms the basis for a range of products, including emollients, flavors and fragrance oils and diesel fuel. The Business’s subsidiaries are Amyris Brasil Ltda. and Amyris Fuels, LLC..